^
Association details:
| Biomarker: | PAK4 deletion |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
998P - The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients
Published date:
09/14/2020
Excerpt:
To our knowledge, this was the largest cohort studying the mutational landscape of biomarkers associated with HP in response to ICIs in Chinese HCC patients. The high incidence of 11q13 amplification and CDKN2A/B gene loss was observed in the cohort. Therefore, the application of comprehensive genomic profiling companion diagnosis might be necessary in guiding the regimen and ICI treatments.
